Leading health innovation around the world

At LivaNova, we are committed to enhancing shareholder value driven by our mission and values that guide our strategy as a company. We are a strong, market-leading medical technology and innovation company, offering a diverse product portfolio and global reach. Through our work, we are improving the quality of life for every patient, every day.

LivaNova is listed on the NASDAQ stock exchange under the ticker symbol "LIVN."

LivaNova has nearly 4,000 employees worldwide. We are headquartered in London (UK) and maintain a presence in more than 100 countries.

LivaNova Therapeutic Areas

We have a strong legacy as leaders in neuromodulation and cardiovascular solutions, providing products and therapies in distinct therapeutic areas to treat the head and heart. These include:

Difficult-to-Treat Depression
Our VNS Therapy® System, SYMMETRY, treats patients with difficult-to-treat depression (DTD) and may provide better outcomes and symptom improvement. We are conducting the RECOVER clinical study to further evaluate the benefits of VNS Therapy for Depression. Discover more

Drug-Resistant Epilepsy
Our VNS Therapy® System for drug-resistant epilepsy has treated more than 125,000 patients around the world. VNS Therapy can lead to fewer seizures, shorter seizures and better recovery after seizures. Discover more

Obstructive Sleep Apnea
Our THN Sleep Therapy includes an implantable device called the aura6000. The CPAP-alternative uses electrical pulses to treat Obstructive Sleep Apnea. Discover more

Advanced Circulatory Support
We’ve created a cardiopulmonary support system that is designed to be powerful, yet simple to use, in emergency situations. The platform centers around the LifeSPARC pump and controller, along with ready-to-deploy kits for different interventions. Discover more

Heart Failure
With Autonomic Regulation Therapy (ART) for heart failure, we strive to fix the heart by balancing the brain. ART uses a variant of VNS Therapy® called VITARIA®. It aims to correct an imbalance that causes the heart to not pump enough blood. Discover more

As the world’s leading cardiopulmonary bypass company, we make the S5® Heart-Lung Machine, oxygenators, and other products and systems for perfusion. Discover more

Heart Valves
We offer a range of valves and rings for heart valve repair and replacement. This includes the only sutureless surgical aortic tissue valve platform on the market, Perceval® and Perceval Plus. Discover more

Pro forma revenues by geography 1

  • Europe
  • United States
  • Rest of World

1) Rounded numbers based on full-year 2020 revenue.

Pro forma revenues by business 1

  • Cardiovascular
  • Neuromodulation

1) Rounded numbers based on full-year 2020 revenue.


Featured News & Events

LivaNova Reports First Quarter 2021 Results

Apr 28, 2021
Read News

LivaNova and Verily Announce First Patient Enrolled in Study to Evaluate Treatment Effectiveness for Patients Living with Depression

Apr 26, 2021
Read News

LivaNova Receives FDA 510(k) Clearance for B-Capta, the New In-Line, Blood-Gas Monitoring System Integrated Into the S5 Heart-Lung Machine

Apr 20, 2021
Read News

Q1 2021 LivaNova PLC Earnings Conference Call

Apr 28, 2021 at 7:00 AM EDT
See Event

LivaNova Education Series: Cardiopulmonary – Nearly Half a Century of Technology

Apr 14, 2021 at 11:00 AM EDT
See Event

Q4 and Full Year 2020 LivaNova PLC Earnings Conference Call

Feb 24, 2021 at 8:00 AM EST
See Event
Performance Dashboard

Data Provided by Refinitiv. Minimum 15 minutes delayed.